Two Sets Of Short Path Molecular Distillation Systems Were Installed In Fengyuan Group

- Aug 06, 2018-

Last year, Fengyuan group ordered one set short path molecular distillation system to be used in drug raw material experiment. They are very satisfied with our quality and high cost performance. Today, customer would like to order two sets FMD-150WFE for the headquarters laboratory. FMD-150WFE is the upgrade configuration of FMD-150, which has the advantages of heating feeding materials and heat preservation of outlet materials. It is especially suitable for distillation of high melting point and high viscosity materials.

In addition, the two sets of equipment have added external condenser to prevent volatile corrosive gas from corroding the vacuum pump, one of which has also upgraded the waste gas treatment.

The customer gave us a high evaluation of our products!

2018.04.27, another two sets of short path molecular distillation systems were installed in Fengyuan Group.

Anhui Fengyuan Pharmaceutical Co., Ltd. (hereinafter referred to as the "bbca Pharmaceutical") is the largest state-owned Pharmaceutical enterprise in Anhui province, the national recognition of the high and new technology enterprise, the enterprise of Anhui province, Anhui province, the Pharmaceutical industry's first listed company, in 2006 was awarded the "people trust medicine brand", the company's total assets 1.2 billion yuan, the staff of nearly 5000 people, 2007, 2008, 2008 for three consecutive years was named China's Pharmaceutical industry. Bbca pharmaceutical co., which owns five pharmaceutical enterprises, two drug packaging materials production enterprises, four pharmaceutical marketing companies, a large pharmacy chain companies, two stock-sharing companies, 44 through the GMP certification of the production line. Products involved in biological, pharmaceutical, chemical, pharmaceutical, proprietary Chinese medicine three areas cover antipyretic analgesic, fu, nervous system, cardiovascular and urinary system, nutrition classes, antibiotics such as 7 major categories, more than 10 formulations, more than 300 varieties. It has the independent intellectual property rights of many kinds of new drugs in different countries and many products. Bbca pharmaceutical company implemented a comprehensive market cultivation and development strategy, more than 30 provinces, municipalities and autonomous regions across the country set up sales offices, constructed by large and medium-sized cities in China, economic developed area, and large and medium-sized hospital orderly and efficient sales network, and some products successfully enter the international market.